JP2004115440A - Calorigenic sympathetic nerve activator and composition containing the same - Google Patents
Calorigenic sympathetic nerve activator and composition containing the same Download PDFInfo
- Publication number
- JP2004115440A JP2004115440A JP2002281453A JP2002281453A JP2004115440A JP 2004115440 A JP2004115440 A JP 2004115440A JP 2002281453 A JP2002281453 A JP 2002281453A JP 2002281453 A JP2002281453 A JP 2002281453A JP 2004115440 A JP2004115440 A JP 2004115440A
- Authority
- JP
- Japan
- Prior art keywords
- aralia
- nelumbo
- lotus
- sympathetic nerve
- thermogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、熱産生交感神経活性化剤及びそれを含有する経口投与用の組成物に関する。
【0002】
【従来の技術】
栄養状態が改善されすぎた現代に於いて、肥満は大きな社会問題となっている。これを反映して、日本に於いては「ダイエット」と言う言葉は、食事制限による摂取カロリーの低減を直接的に意味するようになっている。又、所謂健康食品に於いても、「ダイエット」を訴求したものが少なくない。この様な「ダイエット」を訴求した健康食品は、大きく分けると、1)グルコマンナンの如く非消化性繊維或いはそれの作るゲル化物を投与し、物理的に食物が消化器に入らないように抑制する、(特開平6−181702号)2)カプサイシン乃至はキンギンカ等の様に熱産生タンパク質(Uncoupling Protein;UCP)の発現を促進し、脂質の熱エネルギーへの変換を高め、脂質の蓄積を抑制する(特開2000−189108号)、の2種が存在する。しかしながら、熱産生を司る、熱産生交感神経を活性化させる方法は知られていない。更に、ウコギ科のタラノキ属植物及びスイレン科乃至はハス科のハス属植物のエキスと生体に於ける熱産生の関係も全く知られていない。又、複合的な脂質蓄積システムに於いて、過剰な脂質の蓄積を抑制するためには、単一のメカニズムのみならず、複合的なメカニズムでの対応が必要であり、その意味で新しい脂質蓄積抑制のメカニズムの解明と脂質蓄積抑制素材の開発が望まれていた。
【0003】
一方、ウコギ科(Araliaceae)のタラノキ属植物(Aralia)が、民間薬として、発汗、解熱、鎮痛薬とし、頭痛、歯痛、リウマチ、神経痛に用いられること、及び、スイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)が収斂作用、鎮静作用、経度の滋養作用を目的に民間薬として使用されることも知られていたが、これらのエキスが、熱産生交感神経活性化作用を有することは全く知られていなかったし、熱産生交感神経活性化を目的に経口的に投与されることも行われていなかった。
【0004】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、新しい脂質蓄積抑制のメカニズムに基づいた脂質蓄積抑制素材を提供することを課題とする。
【0005】
【課題の解決手段】
本発明者らは、この様な状況に鑑みて、新しい脂質蓄積抑制のメカニズムに基づいた脂質蓄積抑制素材を求めて、鋭意研究努力を重ねた結果、ウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスが熱産生交感神経を活性化させる作用を有しており、かかる作用により、脂質蓄積を抑制できることを見出し、発明を完成させるに至った。即ち、本発明は、以下に示す技術に関するものである。
(1)ウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスからなる熱産生交感神経活性化剤。
(2)ウコギ科(Araliaceae)のタラノキ属植物(Aralia)が、タラノキ(Aralia elata)、シナタラノキ(Aralia chinensis) 、アメリカタラノキ(Aralia spinosa)、メダラ、(Aralia elata Seemann var.canescens Nakai)、ウド(Aralia cordata)及びミヤマウド(Aralia glabra)から選択されるものであることを特徴とする、(1)に記載の熱産生交感神経活性化剤。
(3)ハス属植物(Nelumbo)がハス (Nelumbo nucifera Gaertner)、中国姫蓮(Nelumbo spec.)、桜蓮 (Nelumbo nucifera cv. Ouren)、紅舞姫蓮 (Nelumbo nucifera cv. Benimaihiren)、キバナバス(Nelumbo lutea)、ネルンボ ヌシフェラ カスピカム(Nelumbo nucifera cv. Cuspicum)及びネルンボ ハイブリダ(睡蓮;Nelumbo hybrida)から選択されるものであることを特徴とする、(1)に記載の熱産生交感神経活性化剤。
(4)エキスが、極性溶媒抽出物乃至はその溶媒除去物である(1)〜(3)何れか1項に記載の熱産生交感神経活性化剤。
(5)(1)〜(4)何れか1項に記載の熱産生交感神経活性化剤を含有する、経口投与用の組成物。
(6)ウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスを含有する、熱産生交感神経活性化用の経口投与用の組成物。
(7)ウコギ科(Araliaceae)のタラノキ属植物(Aralia)が、タラノキ(Aralia elata)、シナタラノキ(Aralia chinensis) 、アメリカタラノキ(Aralia spinosa)、メダラ、(Aralia elata Seemann var.canescens Nakai)、ウド(Aralia cordata)及びミヤマウド(Aralia glabra)から選択されるものであることを特徴とする、(6)に記載の熱産生交感神経活性化用の経口投与用の組成物。
(8)ハス属植物(Nelumbo)がハス (Nelumbo nucifera Gaertner)、中国姫蓮(Nelumbo spec.)、桜蓮 (Nelumbo nucifera cv. Ouren)、紅舞姫蓮 (Nelumbo nucifera cv. Benimaihiren)、キバナバス(Nelumbo lutea)、ネルンボ ヌシフェラ カスピカム(Nelumbo nucifera cv. Cuspicum)及びネルンボ ハイブリダ(睡蓮;Nelumbo hybrida)から選択されるものであることを特徴とする、(6)に記載の熱産生交換神経活性化用の経口投与用の組成物。
【0006】
【発明の実施の形態】
(1)本発明の熱産生交感神経活性化剤
本発明の熱産生交感神経活性化剤は、ウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスからなる。かかるエキスを作成する、ウコギ科(Araliaceae)のタラノキ属植物(Aralia)としては、タラノキ(Aralia elata)、シナタラノキ(Aralia chinensis) 、アメリカタラノキ(Aralia spinosa)、メダラ、(Aralia elata Seemann var.canescens Nakai)、ウド(Aralia cordata)及びミヤマウド(Aralia glabra)から選択されるものが好適に例示できる。特に、ウド(Aralia cordata)及びミヤマウド(Aralia glabra)を用いるのが好ましい。使用する部位としては、特段の限定が無いが、根茎を用いることが特に好ましい。又、エキスを作成するのに使用できるスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)としては、ハス (Nelumbo nuciferaGaertner)、中国姫蓮(Nelumbo spec.)、桜蓮 (Nelumbo nucifera cv. Ouren)、紅舞姫蓮 (Nelumbo nucifera cv. Benimaihiren)、キバナバス(Nelumbo lutea)、ネルンボ ヌシフェラ カスピカム(Nelumbo nucifera cv. Cuspicum)及びネルンボ ハイブリダ(睡蓮;Nelumbo hybrida)から選択されるものが好適に例示できる。これらの内では、ハス (Nelumbo nucifera Gaertner)及びキバナバス(Nelumbo lutea)を用いるのが特に好ましい。使用部位としては、特段の限定はないが、種子の仁を用いることが特に好ましい。本発明で言う、これらのエキスとは、植物体そのものを粉砕など加工した加工物、植物体乃至はその加工物に溶媒を加え、抽出した抽出物、抽出物から溶媒を除去した溶媒除去物、抽出物乃至はその溶媒除去物を更にカラムクロマトグラフィーや液液抽出などで分画精製した、分画精製物などの総称を意味する。本発明の熱産生交感神経活性化剤としては、溶媒抽出物或いはその溶媒除去物が好ましい。溶媒抽出物は、植物体乃至はその加工物に、1〜10重量倍の溶媒を加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬することにより製造することができる。溶媒としては、通常この様な抽出に用いられている溶媒であれば特段の限定はされないが、極性溶媒が特に好ましく例示できる。極性溶媒としては、水、エタノール、イソプロパノール、ブタノール、1,3−ブタンジオール等のアルコール類、酢酸エチルや蟻酸メチルなどのエステル類、ジエチルエーテルやテトラヒドロフラン等のエーテル類、アセトンやメチルエチルケトン等のケトン類、クロロホルムや塩化メチレン等のハロゲン化炭化水素類、アセトニトリル等のニトリル類などが好ましく例示でき、水及び/又はアルコールが特に好ましい。これは、溶出特性と安全性の観点からである。かくして得られたウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスは、後記実施例に示す如く、優れた熱産生交感神経活性化作用を有する。この様な作用により、生体全体の熱エネルギー産生を促進し、過剰に存在する脂質を熱に変換させ、脂質の蓄積を抑制する。更に、次に示す如く、ウコギ科(Araliaceae)のタラノキ属植物(Aralia)のエキス又はスイレン科(Nymphacaccac)乃至はハス科(Nelumbonaceae)のハス属植物(Nelumbo)のエキスは、熱産生タンパク質も活性化するため、二つの異なるメカニズムにより、脂質の蓄積を抑制することができる。この意味に於いても、本発明の熱産生交感神経活性化剤は、従来にない優れた効果を有すると言える。本発明の熱産生交感神経活性化剤の好ましい用量は、成人1日あたり、200〜10000mgを1回乃至は数回に分けて経口的に摂取することである。特に好ましい用量は一回の摂取量が200mg以上であることである。この為には、本発明の経口投与用の組成物に於いては、本発明の熱産生交感神経活性化剤を50〜90重量%含有することが好ましい。
【0007】
<製造例1>
ウコギ科(Araliaceae)のウド(Aralia cordata)の老根及び細い根500gに5Lの50%エタノールを加え、攪拌しながら2時間、90℃で加熱し、室温まで冷却した後、濾過して不溶物を取り除き、更に減圧濃縮をして、その後、凍結乾燥し、本発明の熱産生交感神経活性化剤1を得た。
【0008】
<製造例2>
ハス科(Nelumbonaceae)のハス(Nelumbo nucifera Gaertner)の種子の仁(蓮肉)500gに5Lの50%エタノールを加え、一週間室温で抽出後、濾過して不溶物を取り除き、更に減圧濃縮をして、その後、凍結乾燥し、本発明の熱産生交感神経活性化剤2を得た。
【0009】
マウスの肩胛骨間褐色脂肪組織中の熱産生タンパク質の発現促進実験
8週齢のddY系雄性マウスを9匹を一群とし、飼料として基礎飼料MFに精製ラードを20%添加し、被験物質として熱産生交感神経活性化剤1又は2を5%添加し、マウスに4週間自由摂取させた。その後、肩胛骨間褐色脂肪組織を採取し、遠心分離により粗ミトコンドリア画分を得た。画分中のタンパク質濃度を5μg/10μLに希釈後、ウェスタンブロットによる熱産生タンパク質の検出を行った。検出されたバンド強度を数値化し、ベヒクル群の値を100とした時の相対的な熱産生タンパク質含量を求めた。結果を表1に示す。これより、本発明の熱産生交感神経活性化剤は、熱産生タンパク質の発現も促進し、脂質を熱エネルギーに変換していることがわかる。
【0010】
【表1】
【0011】
(2)本発明の経口投与用の組成物
本発明の経口投与用の組成物は、上記本発明の熱産生交感神経活性化剤を含有することを特徴とする。かかる熱産生交感神経活性化剤は唯一種を含有させることもできるし、二種以上を組み合わせて含有させることもできる。本発明に言う経口投与用の組成物とは、経口で投与される製剤の総称を意味し、健康食品を含めた食品、飲料、経口投与医薬品等を包含する。本発明の経口投与用の組成物としては、食品が特に好ましい。これは、ウコギ科のタラノキ属植物及びスイレン科乃至はハス科のハス属植物の何れの植物も食品としての長い実績を有するためである。本発明の経口投与用の組成物は、必須成分であるウコギ科のタラノキ属植物及びスイレン科乃至はハス科のハス属植物のエキス以外に、通常上記の組成物で使用されている任意の成分を含有することができる。かかる任意成分としては、白糖等の糖衣剤、乳糖等の賦形剤、デンプンや結晶セルロースなどの崩壊剤、ゼイン、ゼラチン、シェラック等の被覆剤、ヒドロキシプロピルセルロースなどの結合剤、大豆レシチン、ショ糖脂肪酸エステル等の界面活性剤、ステアリン酸マグネシウム、タルク、ロウ類等の滑沢剤、軽質無水ケイ酸、乾燥水酸化アルミニウムゲル等の流動促進剤、生理食塩水、ブドウ糖水溶液等の希釈剤、矯味矯臭剤、着色剤、殺菌剤、防腐剤、香料等が好ましく例示できる。本発明の経口投与用の組成物は、必須成分の本発明の熱産生交感神経活性化剤と任意の成分を常法に従って処理することにより製造することができる。
【0012】
【実施例】
以下に、実施例を挙げて、本発明について更に詳細に説明を行うが、本発明が、かかる実施例にのみ限定されないことは言うまでもない。
【0013】
<実施例1>
熱産生交感神経活性化剤1を用いて、熱産生交感神経活性化用の経口投与組成物を作成した。即ち、重量50mgのカプセルに熱産生交感神経活性化剤1を100mg充填し、本発明の経口投与用の組成物1(健康食品)を得た。
【0014】
<実施例2>
熱産生交感神経活性化剤2を用いて、熱産生交感神経活性化用の経口投与組成物を作成した。即ち、重量50mgのカプセルに熱産生交感神経活性化剤2を100mg充填し、本発明の経口投与用の組成物2(健康食品)を得た。
【0015】
<実施例3>
ボランティアを用いて、実施例1、2の熱産生交感神経活性化用の経口投与組成物1、2の、熱産生交感神経への作用を調べた。即ち、1群3人、3群計9名を用い、1群はカプセルのみを服用し、1群は実施例1の熱産生交感神経活性化用の組成物1を2カプセル(200mg)を服用し、残る1群は実施例2の熱産生交感神経活性化用の組成物2を2カプセル(200mg)を服用し、酸素マスクを付け、呼気を集めた。又、心電図も装着した。呼気の炭酸ガスと酸素の割合より、常法に従い呼吸商(RQ:Respiratory Quotient)を求め、心電図の波形のパワースペクトル分析((1)Hidetoshi Ue et.al. Annals of Noninvasive Electrocardiology(2000)5, 336−345、(2)International J. obesity(1999)23,793−800)から、熱産生交感神経の活動指標(心拍変動パワー)を求めた。心拍変動パワーの大きさが大きいほど、熱産生に関与する交感神経の活動度が高く、熱産生を生体に促していることを示す。心拍変動パワーの結果を図1に示す。これより、本発明の熱産生交感神経活性化用の組成物が、熱産生交感神経を活性化し、脂質代謝を高め、脂質を優先的に燃焼させていることがわかる。
【0016】
<実施例4>
以下に示す処方に従って、本発明の経口投与用の組成物である食品を作成した。即ち、イの成分を流動層造粒装置に仕込み、20%エタノール20重量部を噴霧しながら流動層造粒を行い、40℃で5時間送風乾燥した後、100mg錠に打錠成形し、これに糖衣パンにて、ロの液を噴霧、送風しながら被覆を行い、150mg錠に加工し、本発明の熱産生交感神経活性化用の組成物3(健康食品)を得た。
イ
結晶セルロース 50 重量部
ヒドロキシプロピルセルロース 5 重量部
熱産生交感神経活性化剤1 45 重量部
ロ
ゼイン 9 重量部
カプリル酸モノグリセリド 1 重量部
エタノール 90 重量部
【0017】
<実施例4>
以下に示す処方に従って、本発明の経口投与用の組成物である食品を作成した。即ち、イの成分を流動層造粒装置に仕込み、20%エタノール20重量部を噴霧しながら流動層造粒を行い、40℃で5時間送風乾燥した後、100mg錠に打錠成形し、これに糖衣パンにて、ロの液を噴霧、送風しながら被覆を行い、150mg錠に加工し、本発明の熱産生交感神経活性化用の組成物4(健康食品)を得た。
イ
結晶セルロース 50 重量部
ヒドロキシプロピルセルロース 5 重量部
熱産生交感神経活性化剤2 45 重量部
ロ
ゼイン 9 重量部
カプリル酸モノグリセリド 1 重量部
エタノール 90 重量部
【0018】
【発明の効果】
本発明によれば、新しい脂質蓄積抑制のメカニズムに基づいた脂質蓄積抑制素材を提供することができる。
【図面の簡単な説明】
【図1】実施例2の心電図のパワースペクトル分析の結果を示す図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a thermogenic sympathetic nerve activator and a composition containing the same for oral administration.
[0002]
[Prior art]
Obesity has become a major social problem in today's nutritionally improved state. Reflecting this, in Japan, the term "diet" has come to directly mean a reduction in calorie intake due to dietary restriction. Also, in so-called health foods, there are not a few that claim "diet". Health foods that promoted such "diet" can be broadly divided into 1) administration of non-digestible fiber such as glucomannan or gelled product made from it, to prevent food from physically entering the digestive system. (JP-A-6-181702) 2) Promote the expression of a thermogenic protein (Uncoupling Protein; UCP) such as capsaicin or goldfish, enhance the conversion of lipids to heat energy, and suppress the accumulation of lipids (Japanese Patent Laid-Open No. 2000-189108). However, there is no known method for activating thermogenic sympathetic nerve, which controls thermogenesis. Furthermore, there is no known relationship between the extracts of the plants belonging to the genus Araliaceae and the extracts of the plants belonging to the genus Lotus belonging to the genus Lotus or the family Lotus. In addition, in a complex lipid accumulation system, in order to suppress the accumulation of excess lipid, not only a single mechanism but also a complex mechanism is necessary. Elucidation of the mechanism of suppression and development of lipid accumulation suppressing materials have been desired.
[0003]
On the other hand, a plant of the genus Araliaceae (Araliaceae) is used as a folk medicine for sweating, antipyretic, and analgesic, and is used for headache, toothache, rheumatism, neuralgia, and Nymphacaccac or Lotus It has also been known that the lotus plant (Nelumbo) of the family Nelumbonaceae is used as a folk medicine for the purpose of astringent action, sedative action, and nourishment of longitude, but these extracts are used to activate thermogenic sympathetic nerves. It was not known to have any effect, nor was it administered orally for the purpose of activating thermogenic sympathetic nerves.
[0004]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and it is an object of the present invention to provide a lipid accumulation suppressing material based on a new lipid accumulation suppressing mechanism.
[0005]
[Means for solving the problem]
In view of such a situation, the present inventors have intensively researched for a lipid accumulation suppressing material based on a new lipid accumulation suppressing mechanism. As a result, the Araliaceae plant of the genus Aralia (Araliae) has been developed. ) Or an extract of the Lotus plant (Nelumbo) of the family Nymphacaccac or Nelumbonaceae has the effect of activating thermogenic sympathetic nerves, and the effect can suppress lipid accumulation. And completed the invention. That is, the present invention relates to the following technology.
(1) A heat-generating sympathetic nerve activator comprising an extract of a plant belonging to the genus Araliaceae (Araliaceae) or an extract of a plant belonging to the genus Lotus (Nymphacaccac) or a plant belonging to the genus Lotus (Nelumbonaceae).
(2) Plants of the genus Araliaceae (Araliaceae) belonging to the genus Aralia (Aralia elata, Aralia ena sana sara ana ena sana sara ena ena ena sana sara ena ena ena ana eta ana eta ana eta ana eta nata) The heat-generating sympathetic nerve activator according to (1), wherein the activator is selected from the group consisting of Aralia corddata) and beetle (Aralia grabra).
(3) Lotus plant (Nelumbo) is a lotus (Nelumbo nucifera Gaertner), a Chinese princess lotus (Nelumbo spec.), A cherry blossom lotus (Nelumbo nucifera cv. Ouren), and a red princess princess (Nelumbo namiba namibu nife navi namibu nica niva namibu navi namiba namibu namibu namibu nife navi namibu nife navi namiba nevi navi namibu nife navi namiba). lutea), Nelumbo nucifera cv. Cuspicum and Nerumbo hybrida (water lily; Nelumbo hybrida), the thermogenic sympathetic nerve activator according to (1), which is selected from the group consisting of:
(4) The thermogenic sympathetic nerve activator according to any one of (1) to (3), wherein the extract is a polar solvent extract or a solvent-removed product thereof.
(5) A composition for oral administration, comprising the thermogenic sympathetic nerve activator according to any one of (1) to (4).
(6) A heat-generating sympathetic nerve activating method containing an extract of a plant belonging to the genus Araliaceae (Araliaceae) or an extract of a plant belonging to the genus Lotus (Nymphaaccacac) or a plant belonging to the lotus family (Nelumbonaceae). A composition for oral administration of.
(7) Plants of the genus Araliaceae (Araliaeaae) are aralia plants (Aralia), Aralia elata, Aralia chinensis, Aralia spinosa, Medara, (Aralia ena usa ana eta ana eta ana eta ana eta ana eta nata) The composition for oral administration for activating thermogenic sympathetic nerve according to (6), which is selected from Aralia cordata) and beetle (Aralia grabra).
(8) Lotus plant (Nelumbo) is a lotus (Nelumbo nucifera Gaertner), a Chinese princess lotus (Nelumbo spec.), A cherry blossom lotus (Nelumbo nucifera cv. Ouren), and a red princess princess (Nelumbo namibena namibu nica niva namibu nife navi namiba namibu nife navi namibu nica nevi nba namibu namibu namibu nife navi namiba nevi nba namibu nife navi nu neba nevi navi nu neba nevi navi namibu nife navi namiba) lutea), Nelumbo nucifera cv. Cuspicum and Nerumbo hybrida (Nelumbo hybrida), characterized in that they are selected from the group consisting of: Composition for administration.
[0006]
BEST MODE FOR CARRYING OUT THE INVENTION
(1) The heat-generating sympathetic activator of the present invention is a heat-generating sympathetic activator of the present invention. It consists of an extract of a plant of the genus Lotus (Nelumboaceae). The aralia plants of the family Araliaceae (Aralia) that produce such extracts include: Aralia (araria elata), Aralia chinensis, Aralia spinosa, Medara (Araena sane arasa ansa ane sarena sarenae sarenae sarenae aris). ), Udo (Aralia corddata), and beetle (Aralia glabra) can be preferably exemplified. In particular, it is preferable to use udo (Aralia corddata) and beech (Aralia glabra). The site to be used is not particularly limited, but it is particularly preferable to use a rhizome. In addition, as a lotus plant (Nelumboaceae) belonging to the family Nymphacaccac or Nelumbonaceae, which can be used for producing the extract, lotus (Nelumbo nucifera Gaertner), Chinese princess lotus (Nelumbo spec.), And cherry blossom lotus (Nelumbo spec.) Nelumbo nucifera cv. Ouren, Nelumbo nucifera cv. Benimaihiren, Kibana bus (Nelumbo lutea), Nelumbo nushifera Cuibuna and Nebubo nucifer b. Can be exemplified. Among these, it is particularly preferable to use lotus (Nelumbo nucifera Gaertner) and kibanabasu (Nelumbo lutea). The site to be used is not particularly limited, but it is particularly preferable to use seed kernels. In the present invention, these extracts are a processed product obtained by processing a plant itself such as pulverization, a plant or a processed product obtained by adding a solvent to the plant, or an extracted extract, a solvent-removed product obtained by removing a solvent from the extract, The term refers to a generic term for fractionated and purified products obtained by further fractionating and purifying the extract or its solvent-removed product by column chromatography or liquid-liquid extraction. As the thermogenic sympathetic nerve activator of the present invention, a solvent extract or a solvent-removed product thereof is preferable. The solvent extract can be produced by adding a solvent in an amount of 1 to 10 times by weight to a plant or a processed product thereof and immersing the plant at room temperature for several days or at a temperature near the boiling point for several hours. The solvent is not particularly limited as long as it is a solvent usually used for such extraction, but a polar solvent can be particularly preferably exemplified. Examples of the polar solvent include water, alcohols such as ethanol, isopropanol, butanol and 1,3-butanediol, esters such as ethyl acetate and methyl formate, ethers such as diethyl ether and tetrahydrofuran, and ketones such as acetone and methyl ethyl ketone. And halogenated hydrocarbons such as chloroform and methylene chloride; nitriles such as acetonitrile; and water and / or alcohol are particularly preferable. This is from the viewpoint of elution characteristics and safety. The extract of the plant of the genus Araliaceae (Araliaea) and the extract of the plant of the genus Lotus (Nymphaaccacac) or the plant of the genus Lotus (Nelumbonaceae) belonging to the genus Lotus (Nelumbo) obtained as described above are excellent. It has a thermogenic sympathetic nerve activating effect. By such an action, thermal energy production of the whole organism is promoted, excess lipid is converted into heat, and accumulation of lipid is suppressed. Furthermore, as shown below, the extract of the plant of the genus Araliaceae (Araliaceae) or the extract of the plant of the genus Lotus (Nymphaaccacac) or the plant of the genus Lotus (Nelumbonaceae) of the genus Lotus (Nelumbo) is also active in heat-producing proteins. Therefore, lipid accumulation can be suppressed by two different mechanisms. In this sense, the thermogenic sympathetic nerve activator of the present invention can be said to have an unprecedented superior effect. A preferred dose of the thermogenic sympathetic nerve activator of the present invention is to take 200 to 10000 mg orally in one or several divided doses per day for an adult. A particularly preferred dose is a single dose of 200 mg or more. For this purpose, the composition for oral administration of the present invention preferably contains 50 to 90% by weight of the thermogenic sympathetic nerve activator of the present invention.
[0007]
<Production Example 1>
5 L of 50% ethanol was added to 500 g of old and thin roots of Aralia cordae (Araliaceae), heated at 90 ° C. for 2 hours with stirring, cooled to room temperature, and then filtered to remove insoluble matter. Was removed, and the mixture was further concentrated under reduced pressure, and then freeze-dried to obtain a thermogenic sympathetic nerve activator 1 of the present invention.
[0008]
<Production Example 2>
Five liters of 50% ethanol was added to 500 g of seeds of lotus (Nelumbo nucifera Gaertner) of the lotus family (Nelumbonaceae), extracted at room temperature for one week, filtered to remove insolubles, and further concentrated under reduced pressure. Then, it was freeze-dried to obtain the thermogenic sympathetic nerve activator 2 of the present invention.
[0009]
Experiment for promoting the expression of heat-producing protein in interscapular brown adipose tissue of mice A group of nine 8-week-old ddY-type male mice, 20% of purified lard was added to basal feed MF as a feed, and heat production as a test substance 5% of the sympathetic activator 1 or 2 was added, and the mice were allowed to freely ingest for 4 weeks. Thereafter, brown interscapular adipose tissue was collected and centrifuged to obtain a crude mitochondrial fraction. After diluting the protein concentration in the fractions to 5 μg / 10 μL, detection of heat-producing proteins was performed by Western blot. The detected band intensities were quantified and the relative heat-producing protein content when the value of the vehicle group was set to 100 was determined. Table 1 shows the results. This indicates that the thermogenic sympathetic nerve activator of the present invention also promotes the expression of thermogenic proteins and converts lipids to heat energy.
[0010]
[Table 1]
[0011]
(2) The composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing the above-mentioned thermogenic sympathetic nerve activator of the present invention. Such a thermogenic sympathetic nerve activator may contain only one kind, or may contain two or more kinds in combination. The composition for oral administration as referred to in the present invention means a general term for preparations administered orally, and includes foods including health foods, beverages, orally administered pharmaceuticals, and the like. Food is particularly preferred as the composition for oral administration of the present invention. This is because any of the plants of the genus Araliaceae and the plants of the genus Lotus or the Lotus genus have a long track record as foods. The composition for oral administration of the present invention is an essential component, other than the extract of a plant belonging to the genus Araliaceae and a plant belonging to the genus Lotus belonging to the waterlily or Lotus family, any component that is usually used in the above composition. Can be contained. Such optional ingredients include sugar coatings such as sucrose, excipients such as lactose, disintegrants such as starch and crystalline cellulose, coatings such as zein, gelatin, shellac, binders such as hydroxypropylcellulose, soy lecithin, Surfactants such as sugar fatty acid esters, lubricating agents such as magnesium stearate, talc, waxes, etc., glidants such as light anhydrous silicic acid, dried aluminum hydroxide gel, diluents such as physiological saline and aqueous glucose solutions, Preferred examples include flavoring agents, coloring agents, bactericides, preservatives, and fragrances. The composition for oral administration of the present invention can be produced by treating an essential component of the thermogenic sympathetic nerve activator of the present invention and an optional component according to a conventional method.
[0012]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, but it is needless to say that the present invention is not limited to only these Examples.
[0013]
<Example 1>
An orally administered composition for activating thermogenic sympathetic nerve was prepared using thermogenic sympathetic nerve activator 1. That is, 100 mg of a thermogenic sympathetic nervous activator 1 was filled into a capsule of 50 mg in weight to obtain a composition 1 (health food) for oral administration of the present invention.
[0014]
<Example 2>
An orally administered composition for activating thermogenic sympathetic nerve was prepared using thermogenic sympathetic nerve activator 2. That is, a capsule of 50 mg in weight was filled with 100 mg of the thermogenic sympathetic nerve activator 2 to obtain a composition 2 (health food) for oral administration of the present invention.
[0015]
<Example 3>
The effects of the orally administered compositions 1 and 2 for activating thermogenic sympathetic nerves of Examples 1 and 2 on thermogenic sympathetic nerves were examined using volunteers. That is, 3 groups per group, 9 persons per group, 1 group taking only capsules, 1 group taking 2 capsules (200 mg) of the composition 1 for activating thermogenic sympathetic nerve of Example 1. The other group took 2 capsules (200 mg) of the composition 2 for activating thermogenic sympathetic nerve of Example 2, attached an oxygen mask, and collected exhaled air. An electrocardiogram was also worn. A respiratory quotient (RQ) is obtained from the ratio of carbon dioxide to oxygen in the expiration according to a conventional method, and a power spectrum analysis of an electrocardiogram waveform is performed ((1) Hidetoshi Ue et al. Annas of Noninvasive Electrocardiol 2000). 336-345, (2) International J. obesity (1999) 23, 793-800), an activity index (heart rate variability power) of thermogenic sympathetic nerve was determined. The greater the magnitude of the heart rate variability power, the higher the activity of the sympathetic nerves involved in heat production, indicating that the body is promoting heat production. FIG. 1 shows the results of the heart rate variability power. This indicates that the composition for activating thermogenic sympathetic nerves of the present invention activates thermogenic sympathetic nerves, enhances lipid metabolism, and preferentially burns lipids.
[0016]
<Example 4>
According to the following prescription, a food which is a composition for oral administration of the present invention was prepared. That is, the component (a) was charged into a fluidized bed granulator, and fluidized bed granulation was carried out while spraying 20 parts by weight of 20% ethanol, followed by blowing and drying at 40 ° C. for 5 hours, followed by tableting into 100 mg tablets. Was coated with a sugar-coated bread while spraying and blowing on the solution, and processed into 150 mg tablets to obtain a composition 3 (health food) for activating thermogenic sympathetic nerve of the present invention.
A crystalline cellulose 50 parts by weight Hydroxypropyl cellulose 5 parts by weight Thermogenic sympathetic nerve activator 145 parts by weight Rosein 9 parts by weight Caprylic acid monoglyceride 1 part by weight Ethanol 90 parts by weight
<Example 4>
According to the following prescription, a food which is a composition for oral administration of the present invention was prepared. That is, the component (a) was charged into a fluidized bed granulator, and fluidized bed granulation was carried out while spraying 20 parts by weight of 20% ethanol, followed by blowing and drying at 40 ° C. for 5 hours, followed by tableting into 100 mg tablets. The product was coated with a sugar-coated bread while spraying and blowing the solution of B, and processed into 150 mg tablets to obtain a composition 4 (health food) for activating thermogenic sympathetic nerve of the present invention.
A crystalline cellulose 50 parts by weight Hydroxypropyl cellulose 5 parts by weight Thermogenic sympathetic nerve activator 2 45 parts by weight Rosein 9 parts by weight Caprylic acid monoglyceride 1 part by weight Ethanol 90 parts by weight
【The invention's effect】
According to the present invention, it is possible to provide a lipid accumulation suppressing material based on a new lipid accumulation suppressing mechanism.
[Brief description of the drawings]
FIG. 1 is a diagram showing a result of power spectrum analysis of an electrocardiogram in Example 2.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002281453A JP4637447B2 (en) | 2002-09-26 | 2002-09-26 | Heat-producing sympathetic nerve activator and composition containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002281453A JP4637447B2 (en) | 2002-09-26 | 2002-09-26 | Heat-producing sympathetic nerve activator and composition containing the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004115440A true JP2004115440A (en) | 2004-04-15 |
JP2004115440A5 JP2004115440A5 (en) | 2005-11-04 |
JP4637447B2 JP4637447B2 (en) | 2011-02-23 |
Family
ID=32275893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002281453A Expired - Lifetime JP4637447B2 (en) | 2002-09-26 | 2002-09-26 | Heat-producing sympathetic nerve activator and composition containing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4637447B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022094A (en) * | 2004-06-10 | 2006-01-26 | Fancl Corp | NEW 3,4-seco-LUPANE TYPE TRITERPENOID SAPONIN COMPOUND |
JP2012012385A (en) * | 2010-05-31 | 2012-01-19 | Shiseido Co Ltd | Sympathetic nerve activator, and cosmetic, food and sundries containing the same |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05123140A (en) * | 1991-11-05 | 1993-05-21 | Sanyo Kaken Kk | Food preservative |
JPH06225723A (en) * | 1993-02-04 | 1994-08-16 | Takano Co Ltd | Food additive |
JPH07298889A (en) * | 1994-05-09 | 1995-11-14 | Tonen Corp | Production of red natural pigment |
JPH0899993A (en) * | 1994-09-29 | 1996-04-16 | Masayuki Yoshikawa | Production of saponins of aralia elata seem., method for isolating the same and use |
JPH08198769A (en) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | Excessive nutrition absorption inhibitor and composition containing the same |
JPH09227398A (en) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | Antiobese agent |
JPH09241127A (en) * | 1996-03-04 | 1997-09-16 | Nonogawa Shoji Kk | Body reducing agent composition for cosmetic |
JPH10287575A (en) * | 1997-04-09 | 1998-10-27 | Ranka Aayurubeedick Haabu Yakuhin Kk | Antiobestic drug |
JP2001270834A (en) * | 2000-01-20 | 2001-10-02 | Magunooru:Kk | Extract from aralia cordata, method for producing the same and disinfectant containing extract from aralia cordata |
-
2002
- 2002-09-26 JP JP2002281453A patent/JP4637447B2/en not_active Expired - Lifetime
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05123140A (en) * | 1991-11-05 | 1993-05-21 | Sanyo Kaken Kk | Food preservative |
JPH06225723A (en) * | 1993-02-04 | 1994-08-16 | Takano Co Ltd | Food additive |
JPH07298889A (en) * | 1994-05-09 | 1995-11-14 | Tonen Corp | Production of red natural pigment |
JPH0899993A (en) * | 1994-09-29 | 1996-04-16 | Masayuki Yoshikawa | Production of saponins of aralia elata seem., method for isolating the same and use |
JPH08198769A (en) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | Excessive nutrition absorption inhibitor and composition containing the same |
JPH09227398A (en) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | Antiobese agent |
JPH09241127A (en) * | 1996-03-04 | 1997-09-16 | Nonogawa Shoji Kk | Body reducing agent composition for cosmetic |
JPH10287575A (en) * | 1997-04-09 | 1998-10-27 | Ranka Aayurubeedick Haabu Yakuhin Kk | Antiobestic drug |
JP2001270834A (en) * | 2000-01-20 | 2001-10-02 | Magunooru:Kk | Extract from aralia cordata, method for producing the same and disinfectant containing extract from aralia cordata |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006022094A (en) * | 2004-06-10 | 2006-01-26 | Fancl Corp | NEW 3,4-seco-LUPANE TYPE TRITERPENOID SAPONIN COMPOUND |
JP2012012385A (en) * | 2010-05-31 | 2012-01-19 | Shiseido Co Ltd | Sympathetic nerve activator, and cosmetic, food and sundries containing the same |
Also Published As
Publication number | Publication date |
---|---|
JP4637447B2 (en) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000086510A (en) | Histamine release inhibitor | |
CN104306651A (en) | Tibetan medicine composition with whitening and freckle removing function and application and preparation method of Tibetan medicine composition | |
WO2018016455A1 (en) | Nourishing tonic | |
TWI503124B (en) | Enamel production enhancers and humectants | |
JP7176790B1 (en) | COMPOSITION FOR IMPROVING SLEEP AND IMPROVING MEMORY, AND ITS PREPARATION AND APPLICATION | |
JP4817087B2 (en) | Bioactive extract | |
JP2017186270A (en) | Inhibitors of sebaceous cell activation | |
TWI478717B (en) | Composition of antrodia camphorata and use thereof | |
JP4637447B2 (en) | Heat-producing sympathetic nerve activator and composition containing the same | |
JP6417576B2 (en) | Soybean seed extract, method for producing the soybean seed extract and use thereof | |
JP2019054791A (en) | Fatigue improving composition | |
JP2701385B2 (en) | Brain edema inhibitor | |
JP3204348B2 (en) | Arteriosclerosis inhibitor and food or medicine containing it | |
JP2004051486A (en) | Thermogenic sympathetic nerve activator | |
JP6981641B2 (en) | PDE5 activity inhibitor | |
JP2003113106A (en) | Expression promoter of uncoupling protein and composition containing the same | |
JP2003113100A (en) | Calorigenic protein-expressing promoter and composition containing the same | |
JP2019210278A (en) | Composition for reducing cholesterol, and method for imparting cholesterol reducing functionality | |
KR20150086928A (en) | Composition for prevention or treatment of influenza virus infection comprising curcuminoid and licorice extracts or fraction thereof | |
EP4151226A1 (en) | Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient | |
JP2004043399A (en) | Blood lipid ameliorant | |
CN110101787B (en) | Heart-clearing and depression-relieving powder, preparation method and application thereof | |
JP4109835B2 (en) | Medicinal extract of persimmon | |
KR20160143628A (en) | Composition for prevention or treatment of influenza virus infection comprising curcuminoid and licorice extracts or fraction thereof | |
JP2000247880A (en) | Fat decomposition-accelerating agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050824 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050824 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20050824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101102 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101124 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20161203 Year of fee payment: 6 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4637447 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |